title: Nasopharyngeal/nasal type NK/T lymphoma: analysis of 23 cases and current review of the literature.
abstract: OBJECTIVE
  This study aims to identify the presenting symptoms, treatment and outcome of patients with nasal natural killer T (NK/T)-cell lymphoma and to find possible differences in survival based on Ann-Arbor stage and international prognostic index (IPI).
  
  
  METHODS
  Computed tomography and biopsy results of 23 patients (15 males, 8 females; mean age 41 years; range 22 to 72 years) with extranodal NK/T-cell lymphoma who were treated at the department of clinical hematology between 1995 and 2011 were retrospectively analyzed.
  
  
  RESULTS
  The median time from onset of clinical symptoms to histological diagnosis was five months. Most patients presented with nasal obstruction (69%) and rhinism (52%). The site of extranodal NK/T-cell lymphoma primarily involved nasal cavity in 39%. Orbital extension was observed in 26%. Lymphomas were classified as stage IE in 30.4%, stage IIE in 47.8% and stage IVE in 21.7%. Nineteen patients received treatment: 10 received chemotherapy plus radiotherapy, nine received chemotherapy only. We used several regimens of chemotherapy including some protocols containing etoposid, L-asparaginase and others without this drugs. Univariate analysis showed that lower IPI score, low Ann-Arbor stage and responsiveness to treatment with both chemotherapy and radiotherapy were significant factors influencing both OS and PFS.
  
  
  CONCLUSIONS
  Nasal type NK/T-cell lymphoma showed a poor response to the conventional anthracycline-based chemotherapy, thereby an investigation for a novel therapy is urgently needed to improve survival.
authors.affiliation: Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia. yosra.benyoussef@laposte.net
authors.forename: Yosra Ben
authors.initials: YB
authors.lastname: Youssef
authors.forename: Iheb
authors.initials: I
authors.lastname: Bougmiza
authors.forename: Zahreddine
authors.initials: Z
authors.lastname: Bouabid
authors.forename: Bechir
authors.initials: B
authors.lastname: Achour
authors.forename: Haifa
authors.initials: H
authors.lastname: Regaieg
authors.forename: Badreddine
authors.initials: B
authors.lastname: Sriha
authors.forename: Malek
authors.initials: M
authors.lastname: Belkadhi
authors.forename: Halima El
authors.initials: HE
authors.lastname: Omri
authors.forename: Abderrahim
authors.initials: A
authors.lastname: Khelif
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D055611:Natural Killer T-Cells; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult